Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of BMCA and GPRC5D Dual Target CAR-T Cells Therapy in Patients With Relapsed or Refractory Multiple Myeloma

NCT05325801 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT05325801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05325801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of BMCA and GPRC5D Dual Target CAR-T Cells Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Zhejiang University
Phase
Phase 1
Overall status
Unknown status
Start date
April 30, 2022
Completion date
March 31, 2025
Enrollment
9 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma